ClinicalTrials.gg
Enrolling by invitationNCT07312136EPSOMIP2Updated Oct 9, 2026

MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study

An observational study in MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis and Advanced Fibrosis, sponsored by Linkoeping University. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Primary conditionSarcopeniaRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sarcopenia
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Sarcopenia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Linkoeping University · Observational

How we know

Updated Oct 9, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
317
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Sarcopenia with a site in Sweden — 6 open to participants now, 6 under way, none of them phase 3. Sarcopenia · Sweden.

Started
2025
with 2 others
Observational
8 of 10
6 open now
Registered
10th of 10
by date
Lead sponsor
2 of 10
Linkoeping University

Among the 10 studies in Sarcopenia with a site in Sweden, this one is one of 3 that started in 2025, is one of 8 observational ones, and was the 10th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

6 of the 10 studies in Sarcopenia with a site in Sweden are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Sarcopenia with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.

The main questions it aims to answer are:

  1. How common are MASLD and advanced liver fibrosis at long-term follow-up?
  2. Which factors are associated with progression or regression of liver fat accumulation and liver fibrosis over time?

Participants will:

  • Undergo a clinical examination and review of medical history.
  • Provide blood, urine, and biobank samples.
  • Undergo liver assessment using vibration-controlled transient elastography (VCTE).
  • Undergo magnetic resonance imaging (MRI) to assess liver fat, liver fibrosis, and body composition.
  • Complete questionnaires regarding lifestyle and physical activity.
  • Undergo physical activity measurements using accelerometers and additional assessments related to blood pressure and sleep apnea.
Read the detailed description

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common chronic liver diseases worldwide and is particularly common among individuals with type 2 diabetes. While many people remain stable over time, some develop progressive liver fibrosis, cirrhosis, hepatocellular carcinoma, and other serious liver-related complications. Reliable methods for identifying patients at greatest risk of disease progression remain limited.

EPSOMIP2 is a prospective observational follow-up study of participants who were previously enrolled in the EPSONIP study (NCT03864510) between 2019 and 2023. In the original study, 317 individuals with type 2 diabetes from primary healthcare centers in Östergötland, Sweden, underwent detailed evaluation of liver disease, metabolic health, physical activity, and body composition.

Participants who completed the original study are invited to undergo a new assessment approximately 6 years after their initial evaluation. The follow-up examination includes clinical assessment, blood and urine sampling, vibration-controlled transient elastography, magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), magnetic resonance elastography (MRE), body composition analysis, questionnaires, physical activity measurements, blood pressure assessments, and biobanking.

By comparing the follow-up findings with data collected during the original EPSONIP study, researchers aim to characterize the long-term natural history of MASLD in type 2 diabetes. The study will evaluate prevalence, progression, and regression of hepatic steatosis and liver fibrosis, and investigate associations with physical activity, body composition, genetic variants, hypertension, obstructive sleep apnea, and other metabolic risk factors.

The study will also investigate the occurrence of clinically significant liver-related outcomes, including decompensated liver disease, hepatocellular carcinoma, liver transplantation, and liver-related mortality. In addition, health-economic analyses will be performed to evaluate strategies for MASLD management and risk stratification.

The overall aim of EPSOMIP2 is to improve understanding of the long-term course of MASLD in individuals with type 2 diabetes and to identify factors associated with progression to advanced liver disease.

03

Conditions studied

  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Cirrhosis
  • Advanced Fibrosis
  • Sarcopenia
  • Obesity & Overweight
  • Type 2 Diabetes
  • Hypertension
  • OSAS (Obstructive Sleep Apneas Syndrome)
  • Metabolic Syndrome

Keywords

  • MASLD
  • Fibroscan
  • PDFF
  • MRE
  • Obesity
  • VCTE
04

In context

Sarcopenia Reclassified

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

This study's planned enrollment of 317 is above the median of 120 across 455 observational studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Linkoeping University is the lead sponsor of 193 studies on the registry; 40 are open to participants now.

Compared within Sarcopenia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who where previously included, and completed the assessments in the EPSONIP study (NCT03864510) between 2019 and 2023 are re-invited to fulfill the same evaluation with additional tests.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously included and completed the assessments in the EPSONIP study (NCT03864510)
  • Age >/= 18 years

Exclusion criteria

Exclusion Criteria:

  • to magnetic resonance imaging
  • Other primary liver disease than MASLD diagnosed after inclusion in the EPSONIP study (NCT03864510)
  • Liver transplantation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
317 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Prevalence of MASLD (MRI-PDFF)

    Number of patients with MASLD measured with MRI-PDFF

    Time frame: From December 2025 to December 2031

  2. Prevalence of MASLD (CAP)

    Number of patients with MASLD measured with CAP

    Time frame: From December 2025 to December 2031

  3. Progression/regression of MASLD (MRI-PDFF)

    Number of patients who progress/regress to/from MASLD between two timepoints as measured with MRI-PDFF

    Time frame: From December 2025 to December 2031

  4. Progression/regression of MASLD (CAP)

    Number of patients who progress/regress to/from MASLD between two timepoints as measured with CAP

    Time frame: From December 2025 to December 2031

  5. Prevalence of advanced fibrosis (VCTE)

    Number of patients with advanced liver disease as defined by VCTE

    Time frame: From December 2025 to December 2031

  6. Prevalence of advanced fibrosis (MRE)

    Number of patients with advanced liver disease as defined by MRE

    Time frame: From December 2025 to December 2031

  7. Prevalence of advanced fibrosis (Clinical signs)

    Number of patients with advanced liver disease as defined by clinical signs of decompensation

    Time frame: From December 2025 to December 2031

  8. Progression/regression of advanced fibrosis (VCTE)

    Progression/regression to/from advanced liver disease as measured with VCTE between two timepoints

    Time frame: From December 2025 to December 2031

  9. Progression/regression of advanced fibrosis (MRE)

    Progression/regression to/from advanced liver disease as measured with MRE between two timepoints

    Time frame: From December 2025 to December 2031

  10. The association between physical activity (IFIS) and prevalent advanced fibrosis

    Liver fibrosis measured according to the primary outcome definitions described above. Physical activity measured with the international fitness scale (IFIS).

    Time frame: From December 2025 to December 2031

  11. The association between physical activity (Actigraph GT3X) and prevalent advanced fibrosis

    Liver fibrosis measured according to the primary outcome definitions described above. Physical activity measured with Actigraph GT3X (accelerometer).

    Time frame: From December 2025 to December 2031

  12. The association between physical activity (IFIS) and risk of progressing to advanced fibrosis

    Liver fibrosis progression measured according to the primary outcome definitions described above. Physical activity measured with the international fitness scale (IFIS).

    Time frame: From December 2025 to December 2031

  13. The association between physical activity (Actigraph GT3X) and risk of progressing to advanced fibrosis

    Liver fibrosis progression measured according to the primary outcome definitions described above. Physical activity measured with Actigraph GT3X (accelerometer).

    Time frame: From December 2025 to December 2031

  14. Genetic factors associated with advanced fibrosis or MASLD progression/regression

    Liver fibrosis and fat measured according to the primary outcome definitions described above. Genes to be analyzed: PNPLA3, TM6SF2, MBOAT7 among others.

    Time frame: From December 2025 to December 2031

  15. Association between body composition and MASLD and/or liver fibrosis and progression/regression thereof

    Liver fibrosis and fat measured according to the primary outcome definitions described above. Body composition measured with AMRA Medical AB's MAsS Scan.

    Time frame: From December 2025 to December 2031

Secondary outcomes

  1. The association of hypertension (weekly blood pressure monitoring) and MASLD with or without signs of advanced fibrosis

    Liver fibrosis and fat measured according to the primary outcome definitions described above. Hypertension measured with weekly blood pressure monitoring.

    Time frame: From December 2025 to December 2031

  2. The association of hypertension (24-hour ambulatory blood pressure monitoring) and MASLD with or without signs of advanced fibrosis

    Liver fibrosis and fat measured according to the primary outcome definitions described above. Hypertension measured with 24-hour ambulatory blood pressure monitoring.

    Time frame: From December 2025 to December 2031

  3. The association between OSAS and MASLD with or without advanced fibrosis

    Liver fibrosis and fat measured according to the primary outcome definitions described above. OSAS measured at university hospital sleep apnea clinic.

    Time frame: From December 2025 to December 2031

  4. Health economic model for disease management

    Markov modelling.

    Time frame: From January 2028 to December 2034

  5. Number of patients that develop symptoms of end-stage liver disease

    Symptoms of end-stage liver disease (e.g., ascites, encephalopathy, varices, HCC) or liver-related death will be recorded through chart review

    Time frame: From December 2025 to December 2034

08

Study locations

1 site
  • Department of Gastroenterology and Hepatology, Linköping University Hospital
    Linköping, Östergötland County 58185, Sweden
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2031, 72 months after the start.

Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 72 months is above that.

Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 31, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2034
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPreviously included and fulfilled evaluationcompleted the assessments in the EPSONIP trialstudy (NCT03864510)
Exclusion criteria
  • EditedContraindication to magnetic resonance imaging
  • EditedOther primary liver disease than MASLD diagnosed after inclusion in the EPSONIP trialstudy (NCT03864510)
Oct 9, 2026
Primary outcomes
6 edited, 2 time frame changed, 7 added, 2 removed, 2 description edited
What changed in the outcomes
  • EditedPrevalence of MASLD (MRI-PDFF)Time frame: 2031 → From December 2025 to December 2031
  • EditedProgression/regression of MASLD (MRI-PDFF)Time frame: 2031 → From December 2025 to December 2031
  • EditedPrevalence of advanced fibrosis (VCTE)Time frame: 2031 → From December 2025 to December 2031
  • EditedProgression/regression of advanced fibrosisMASLD (CAP)Time frame: 2031 → From December 2025 to December 2031
  • EditedThe association between physical activity (IFIS) and prevalent advanced fibrosisTime frame: 2031 → From December 2025 to December 2031
  • EditedThe association between physical activity (Actigraph GT3X) and risk of progressing toprevalent advanced fibrosisTime frame: 2031 → From December 2025 to December 2031
  • AddedPrevalence of MASLD (CAP)Time frame: From December 2025 to December 2031
  • AddedPrevalence of advanced fibrosis (MRE)Time frame: From December 2025 to December 2031
  • AddedPrevalence of advanced fibrosis (Clinical signs)Time frame: From December 2025 to December 2031
  • AddedProgression/regression of advanced fibrosis (VCTE)Time frame: From December 2025 to December 2031
  • AddedProgression/regression of advanced fibrosis (MRE)Time frame: From December 2025 to December 2031
  • AddedThe association between physical activity (IFIS) and risk of progressing to advanced fibrosisTime frame: From December 2025 to December 2031
  • AddedThe association between physical activity (Actigraph GT3X) and risk of progressing to advanced fibrosisTime frame: From December 2025 to December 2031
  • RemovedPredictors of MASLD progression/regressionTime frame: 2031
  • RemovedPredictors of fibrosis progression/regressionTime frame: 2031
  • Time frameGenetic factors associated with advanced fibrosis or MASLD progression/regression2031 → From December 2025 to December 2031
  • Time frameAssociation between body composition and MASLD and/or liver fibrosis and progression/regression thereof2031 → From December 2025 to December 2031
  • DescriptionAssociation between body composition and MASLD and/or liver fibrosis and progression/regression thereof: how it is measured was reworded
  • DescriptionGenetic factors associated with advanced fibrosis or MASLD progression/regression: how it is measured was reworded
Oct 9, 2026
Secondary outcomes
2 edited, 2 time frame changed, 1 added, 2 description edited
What changed in the outcomes
  • EditedThe association of hypertension (weekly blood pressure monitoring) and MASLD (with or withourwithout signs of advanced fibrosis)Time frame: 2031 → From December 2025 to December 2031
  • EditedThe association between OSAS and MASLD (with or withourwithout advanced fibrosis)Time frame: 2031 → From December 2025 to December 2031
  • AddedThe association of hypertension (24-hour ambulatory blood pressure monitoring) and MASLD with or without signs of advanced fibrosisTime frame: From December 2025 to December 2031
  • Time frameHealth economic model for disease management2034 → From January 2028 to December 2034
  • Time frameNumber of patients that develop symptoms of end-stage liver disease2035 → From December 2025 to December 2034
  • DescriptionHealth economic model for disease management: how it is measured was reworded
  • DescriptionNumber of patients that develop symptoms of end-stage liver disease: how it is measured was reworded
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPreviously included and fulfilled evaluationcompleted the assessments in the EPSONIP trialstudy (NCT03864510)
    Exclusion criteria
    • EditedContraindication to magnetic resonance imaging
    • EditedOther primary liver disease than MASLD diagnosed after inclusion in the EPSONIP trialstudy (NCT03864510)
    Primary outcomes 6 edited, 2 time frame changed, 7 added, 2 removed, 2 description edited
    What changed in the outcomes
    • EditedPrevalence of MASLD (MRI-PDFF)Time frame: 2031 → From December 2025 to December 2031
    • EditedProgression/regression of MASLD (MRI-PDFF)Time frame: 2031 → From December 2025 to December 2031
    • EditedPrevalence of advanced fibrosis (VCTE)Time frame: 2031 → From December 2025 to December 2031
    • EditedProgression/regression of advanced fibrosisMASLD (CAP)Time frame: 2031 → From December 2025 to December 2031
    • EditedThe association between physical activity (IFIS) and prevalent advanced fibrosisTime frame: 2031 → From December 2025 to December 2031
    • EditedThe association between physical activity (Actigraph GT3X) and risk of progressing toprevalent advanced fibrosisTime frame: 2031 → From December 2025 to December 2031
    • AddedPrevalence of MASLD (CAP)Time frame: From December 2025 to December 2031
    • AddedPrevalence of advanced fibrosis (MRE)Time frame: From December 2025 to December 2031
    • AddedPrevalence of advanced fibrosis (Clinical signs)Time frame: From December 2025 to December 2031
    • AddedProgression/regression of advanced fibrosis (VCTE)Time frame: From December 2025 to December 2031
    • AddedProgression/regression of advanced fibrosis (MRE)Time frame: From December 2025 to December 2031
    • AddedThe association between physical activity (IFIS) and risk of progressing to advanced fibrosisTime frame: From December 2025 to December 2031
    • AddedThe association between physical activity (Actigraph GT3X) and risk of progressing to advanced fibrosisTime frame: From December 2025 to December 2031
    • RemovedPredictors of MASLD progression/regressionTime frame: 2031
    • RemovedPredictors of fibrosis progression/regressionTime frame: 2031
    • Time frameGenetic factors associated with advanced fibrosis or MASLD progression/regression2031 → From December 2025 to December 2031
    • Time frameAssociation between body composition and MASLD and/or liver fibrosis and progression/regression thereof2031 → From December 2025 to December 2031
    • DescriptionAssociation between body composition and MASLD and/or liver fibrosis and progression/regression thereof: how it is measured was reworded
    • DescriptionGenetic factors associated with advanced fibrosis or MASLD progression/regression: how it is measured was reworded
    Secondary outcomes 2 edited, 2 time frame changed, 1 added, 2 description edited
    What changed in the outcomes
    • EditedThe association of hypertension (weekly blood pressure monitoring) and MASLD (with or withourwithout signs of advanced fibrosis)Time frame: 2031 → From December 2025 to December 2031
    • EditedThe association between OSAS and MASLD (with or withourwithout advanced fibrosis)Time frame: 2031 → From December 2025 to December 2031
    • AddedThe association of hypertension (24-hour ambulatory blood pressure monitoring) and MASLD with or without signs of advanced fibrosisTime frame: From December 2025 to December 2031
    • Time frameHealth economic model for disease management2034 → From January 2028 to December 2034
    • Time frameNumber of patients that develop symptoms of end-stage liver disease2035 → From December 2025 to December 2034
    • DescriptionHealth economic model for disease management: how it is measured was reworded
    • DescriptionNumber of patients that develop symptoms of end-stage liver disease: how it is measured was reworded
    + 3 other changes: verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07312136
Collaborators
University Hospital, Linkoeping, Amra Medical AB
Responsible party
Patrik Nasr (Adj Associate Professor, Docent, Specialist doctor, Linkoeping University) — Principal investigator
First posted
Dec 31, 2025
Start date
Dec 16, 2025
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Oct 9, 2026

Study contacts

Patrik Nasr, M.D., Ph.D.
principal investigator · Department of Health, Medicine and Caring Sciences, Linköping University, and Department of Gastroenterology and Hepatology, Linköping University Hospital, Linköping, Sweden

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion